Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Arrowhead Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.